|本期目录/Table of Contents|

[1]张雪松.达比加群酯治疗老年非瓣膜性心房颤动患者血栓栓塞的效果观察[J].慢性病学杂志,2019,20(12):1792-1794.
　ZHANGXue-song.Effect of dabigatran etexilate on thromboembolism in elderly patients with non-valvular atrial fibrillation[J].,2019,20(12):1792-1794.
点击复制

达比加群酯治疗老年非瓣膜性心房颤动患者血栓栓塞的效果观察

《慢性病学杂志》[ISSN:1674-8166/CN:11-5900/R]

卷:
20
期数:
2019年12期
页码:
1792-1794
栏目:
论　著
出版日期:
2019-12-28

文章信息/Info

Title:
Effect of dabigatran etexilate on thromboembolism in elderly patients with non-valvular atrial fibrillation
作者:
张雪松
北京民航总医院，北京 100025
Author(s):
ZHANGXue-song
BeijingCivil AviationGeneral Hospital,Beijing100025,China Correspondingauthor:ZHANG Xue-song,E-mail:565259993@qq.com
关键词:
达比加群酯; 非瓣膜性心房颤动; 血栓栓塞
Keywords:
Dabigatran etexilate;  Non-valvular atrial fibrillation;  Thromboembolism
分类号:
R541.7
DOI:
-
摘要:
目的 探讨达比加群酯治疗老年非瓣膜性心房颤动血栓栓塞的效果，为临床治疗提供参考。方法 选取 北京民航总医院2018年7月—2019年4月收治的102例老年非瓣膜性心房颤动患者，随机分为观察组和对照组， 各51例。对照组给予法华林治疗，观察组给予达比加群酯治疗。检测并比较两组凝血酶原时间（PT）、凝血活酶 时间（APTT）、国际标化比值（INR）、凝血酶时间（TT）、D-二聚体、血浆纤维蛋白原（FIB）；观察并比较 两组栓塞事件、出血事件和不良反应发生情况。结果 治疗前，两组PT、APTT、INR、TT、D-二聚体和 FIB水平比较，差异无统计学意义（P>0.05）；治疗后，两组PT、APTT、INR、TT和FIB水平均高于本组治 疗前，D-二聚体水平低于本组治疗前，且两组比较，差异有统计学意义（P<0.05）。观察组栓塞事件发生率为 5.88%、出血事件发生率为9.80%，均低于对照组的11.76%和35.29%，差异均有统计学意义（χ 2 =1.097、 9.487，P<0.05）。观察组不良反应总发生率为31.37%，与对照组的29.41%比较，差异无统计学意义（P> 0.05）。结论 达比加群酯可有效减少老年非瓣膜性心房颤动患者栓塞事件和出血事件的发生。
Abstract:
Objective To investigate the effect of dabigatran etexilate on thromboembolism in elderly patients with non-valvular atrial fibrillation. Methods A total of102 elderly patients with non-valvu-lar atrial fibrillation who were treated in Beijing Civil Aviation General Hospital from July 2018 to April2019 were randomly divided into observation group and control group, with51 cases each. The control group was treated with valaclin and the observation group was given dabigatran etexilate. Pro-thrombin time （PT）, thromboplastin time （APTT）, international standardization ratio （INR）, thrombin time（TT）, D-dimer, plasma fibrinogen（FIB）in the two groups were measured and com-pared. Embolism events, bleeding events and adverse reactions were observed and compared. Results Before treatment, there was no significant difference in the levels of PT, APTT, INR, TT, D-di-mer and FIB between the two groups（P>0.05）. After treatment, the PT, APTT, INR and TT levels were increased in two groups, D-dimer level was decreased in two group, and there were sig-nificant differences between the two groups.（P<0.05）. The incidence of embolic events and the inci-dence of bleeding events in the observation group were lower than those in the control group（5.88% vs. 11.76%,9.80% vs.35.29%）, the differences were statistically significant（χ 2 =1.097, 9.487, P< 0.05）. There was no significant difference in total incidence of adverse reactions between the observa-tion group and the control group（31.37% vs.29.41%,P>0.05）. Conclusion Dabigatran etexilate is effective in the treatment of thromboembolism in elderly patients with non-valvular atrial fibrillation.

参考文献/References:

[1] 李鸿飞,兰光明.成都西部地区老年非瓣膜病房颤患者抗凝的治 疗现状[J].昆明医科大学学报,2019,40(4):127-131.[2] 谭璐,张美祥,王树平,等.新型口服抗凝药治疗非瓣膜性房颤安 全性Meta分析[J].中国药业,2019,28(8):67-73. [3] 陈静,石郁,周艳丽.对非瓣膜病心房颤动服用华法林病人加强随 访的抗凝效果观察[J].全科护理,2019,17(8):55-57. [4] 陈冰.达比加群酯治疗老年非瓣膜性心房颤动患者的凝血功能变 化[J].中国医药指南,2019,17(10):174-175. [5] 刘一炫,赵雅红,谢富兰,等. 达比加群酯和华法林在非瓣膜性房 颤抗凝治疗中的效果及安全性对比[J].现代诊断与治疗,2019,30 (2):73-75. [6] 刘万川,刘霄霄.达比加群酯对持续心房颤动患者栓塞事件的预 防效果[J].中国乡村医药,2019,26(7):20-21. [7] 刘文华,陶潞渊,徐恩国.非瓣膜病心房颤动患者血浆miR-486和 miR-150的表达水平及临床意义[J].医学研究杂志,2019(1):78-83. [8] 李微.新型抗凝药与华法林在非瓣膜性房颤患者卒中防治中的应 用效果[J].临床医学研究与实践,2019,4(5):50-52. [9] 王刚,刘强,华军益,等.基于血栓栓塞风险对不同病因所致血瘀 证非瓣膜性房颤患者临床信息的评价研究[J].浙江中医药大学学 报,2019,43(1):38-45. [10] 夏丽萍,陈建明,潘琳,等.非瓣膜性心房颤动患者抗凝治疗的现 状分析[J].心脑血管病防治,2019,19(2):40-42,48.

备注/Memo

备注/Memo:
作者简介：张雪松，硕士研究生，住院医师，研究方向：老年心血管 通信作者：张雪松，E-mail：565259993@qq.com
更新日期/Last Update: 2019-12-28